Samsung Biologics Wins 434.3 Billion Won Biopharma Order

Samsung Biologics has secured a major biopharma contract, worth 434.3 billion won ($324.80 million), with a global pharmaceutical company. This contract, a long-term commitment until December 31, 2031, is expected to provide the company with a stable order backlog. The specific client and product names remain undisclosed due to contractual confidentiality.

This brings Samsung Biologics' cumulative order value since its establishment to $22.3 billion. The company has signed nine contracts this year alone, further solidifying its position in the global bio market, according to market assessments. Samsung Biologics partners with many of the world's top 20 pharmaceutical companies, and its enduring relationships with these global entities likely contributed to the size of this contract.

The company has been actively responding to the growing global demand for biopharmaceuticals and is expanding its diversified supply chains. The new contract is seen as a sign of Samsung Biologics' strengthened management stability, providing secured production volumes for the early 2030s.